A male patient with hypereosinophilic syndrome (HES) underwent an allogeneic blood stem cell transplantation from a female donor following non-myeloablative conditioning consisting of a 2 Gy dose of TBI and fludarabine 30 mg/m 2 intravenously on three days. Before transplantation 100% of the mitotic bone marrow cells of the patient showed a clonal karyotype abnormality. Three months after the transplantation eosinophilia had resolved and a chromosome analysis revealed normal female karyotype. The present study shows that stem cell transplantation after non-myeloablative conditioning may have curative potential for HES.
The prognosis of hypereosinophilic syndrome (HES) with multiple organ dysfunctions is poor, and most treatment modalities are palliative. Probably the only potentially curative treatment for HES is allogeneic stem cell transplantation. [1] [2] [3] [4] [5] We report a patient with HES treated with blood stem cell transplantation following non-myeloablative conditioning.
The patient was a 43-year-old man with HES diagnosed 3 years prior to transplantation. At presentation his blood leukocyte count was 26.5 ϫ 10 9 /l and eosinophil count 4.74 ϫ 10 9 /l. The bone marrow was hypercellular with increased myelopoiesis. The myeloid/erythroid ratio was 10:1. Ten to 15 per cent of bone marrow nucleated cells was eosinophils. In bone marrow karyotype analysis a clonal abnormality, 46,XY,t(5;12)(q31;p12), was observed in 26/36 mitotic cells. At the time of diagnosis HES was complicated by acute myocardial infarction. Within the preceding year the patient had also suffered from deep venous thrombosis complicated with pulmonary embolus. In addition, he had urticaria and itching. A skin biopsy revealed eosinophilic infiltrates. Before transplantation the eosinophilia had been treated with hydroxyurea for 18 months and with three infusions of vincristine in 2 week intervals, with a poor response.
The prognosis with conventional treatments was estimated to be poor. Because of the previous cardiological problems, conventional allogeneic transplantation was considered too risky. The patient did not have an HLA-identical sibling but an A, B, DRB1, DQB1-matched, one C and DPB1 antigen-mismatched unrelated female donor was available. Therefore a transplantation following non-myeloablative conditioning was carried out. The conditioning consisted of TBI, one 2 Gy dose, and fludarabine 30 mg/m 2 intravenously on 3 days. 6 Oral GVHD prophylaxis was initiated on day Ϫ2 with cyclosporin A 12.5 mg/kg/day divided into two doses and mycophenolate mofetil 1 g twice a day for 30 days. 3.5 ϫ 10 6 filgrastim-mobilized blood CD34
ϩ cells/kg were infused on day 0. Table 1 shows the result of the transplantation. The eosinophilia resolved within 14 days and the neutrophil nadir (0.95 ϫ 10 9 /l) was on day ϩ3. The proportion of eosinophilic cells was normal in all bone marrow aspirates after the transplantation. Chimerism was assessed by means of cytogenetic analyses using in situ hybridization with the t(5;12) and Y chromosome as targets. One month post transplantation the percentage of the recipient's cells was 7%, 3% at 2 months and 0% after 3 months. The post-transplant course was complicated by grade III acute GVHD, with manifestation in the skin and in the gut. The onset was on day ϩ23, and later flare-ups took place at 2. months and 4 months after transplantation. The GVHD was treated with two courses of high-dose corticosteroids and the gut GVHD also with infusions of infliximab. In addition, the patient suffered from recurrent CMV viremia, pulmonary aspergillosis, and bacterial infections. He died of fungal infection 12 months after the transplantation.
The present case shows that allogeneic stem cell transplantation after non-myeloablative conditioning is able to eradicate the abnormal cell clone in HES and may have curative potential for this disorder. We are not aware of other reports of allogeneic transplantation after non-myeloablative conditioning for HES.
